An Open-Label, Phase I, Dose-Escalation Study Evaluating the Safety and Tolerability of GDC-0068 in Patients With Refractory Solid Tumors
Allocation: Non-Randomized, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment
Occurrence of adverse events by NCI CTCAE grade and associated dose of GDC-0068
Through study completion or early study discontinuation
Premal Patel, M.D., Ph.D.
Spain: Agencia EspaÃ±ola de Medicamentos y Productos Sanitarios